Drugs / Paeoniflorin
Paeoniflorin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02878863 | Aug 2016 → Mar 2017 | autoimmune hepatitis | Xiaoli Fan | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01600521 Comparator | Nov 2004 → Apr 2011 | rheumatoid arthritis | University of Minnesota | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paeoniflorin | “Paeoniflorin (PAE), the extract from peony (Paeonia lactiflora), is an active ingredient with anti-inflammation properties.” NCT01600521 ↗ |
| Known as | NSC-178886 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303209 ↗ |
| Known as | PAE | “Paeoniflorin (PAE), the extract from peony (Paeonia lactiflora), is an active ingredient with anti-inflammation properties.” NCT01600521 ↗ |
| Known as | Peoniflorin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303209 ↗ |
| Modality | Small molecule | — CHEMBL4303209 ↗ |
| Route | Oral | “PAE was administrated orally 600 mg twice a day for at least 12 months.” NCT01600521 ↗ |